MEDICA.

PROVIDER ALERT

January 21, 2015

Medica Expands Coverage of Continuous Glucose Monitoring Systems

Alert

After reviewing continuous glucose monitoring (CGM) systems for managing diabetes, Medica has determined that real-time CGM using FDA-approved sensor-augmented insulin pump therapy and low-glucose threshold suspend capability (e.g., MiniMed® 530G with Enlite® sensor low-glucose suspend insulin delivery) *are now covered* for the management of Type 1 diabetes mellitus in select individuals. These individuals have not achieved adequate metabolic control despite frequent self-monitoring, as evidenced by:

- Hemoglobin A1C above goal and inconsistent with fingerstick patterns,
- Unexplained wide fluctuations in blood sugar patterns over time,
- Sudden onset hypoglycemic sign/symptoms lending to safety concerns (e.g., otherwise unexplained seizures, loss of consciousness, extreme hypoglycemia, etc.), or
- Nocturnal hypoglycemia.

This benefit determination, which is a follow-up to a **previous Provider Alert** in November 2014, is effective immediately, beginning with January 21, 2015, dates of service. This change applies to all Medica products including government products unless a particular health plan (whether commercial, Medicare or Medicaid) requires different coverage. All other real-time CGM devices using complete closed-loop insulin delivery systems *remain investigative and therefore not covered*.

Action

No action is required. The updated policy related to this change will soon be available online. **See coverage policies at medica.com**.

View previous Alerts | **Contact Medica**

TWITTER FACEBOOK YOUTUBE FORWARD

The address to the right is not for mailing records or claims.

This email was sent by: Medica
401 Carlson Parkway Minnetonka, MN, 55305, USA